Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy

Journal of Pathology

Volumn 235, Issue 1, 2015, Pages 113-124

  Pavlova, Elena V ^a   Archer, Joy ^b   Wang, Susan Z ^a   Dekker, Nick ^c   Aerts, Johannes M F G ^c   Karlsson, Stefan ^d   Cox, Timothy M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Eliglustat; Gaucher disease; GBA1 deficiency; Glycosphingolipids; Lymphoma; Myeloma; UDP glucosylceramide synthase

Indexed keywords

ELIGLUSTAT; GLUCOSYLCERAMIDE; GLYCOSPHINGOLIPID; PARAPROTEIN; SYNTHETASE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GLUCOSYLCERAMIDE SYNTHASE; CERAMIDE GLUCOSYLTRANSFERASE; GLUCOSYLTRANSFERASE; PYRROLIDINE DERIVATIVE; URIDINE DIPHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BIOSYNTHESIS; BLOOD LEVEL; CONTROLLED STUDY; DRUG POTENCY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; GAUCHER DISEASE; LYMPHOCYTE PROLIFERATION; MOUSE; MYELOMA; NONHUMAN; PLASMACYTOMA; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DISEASE MODEL; FEMALE; LYMPHOMA, B-CELL; MALE; METABOLISM; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GAUCHER DISEASE; GLUCOSYLTRANSFERASES; LYMPHOMA, B-CELL; MALE; MICE; PYRROLIDINES; URIDINE DIPHOSPHATE;

EID: 84916227639     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4452     Document Type: Article

References (60)

1. Ries LAG, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2003 [Internet]. National Cancer Institute. Bethesda, MD. [Accessed April 2014]. Available from: http://seer.cancer.gov/csr/1975-2003/
2. de Fost M, Vom Dahl S, Weverling GJ, et al. Increased incidence of cancer in adult Gaucher disease in western Europe. Blood Cells Mol Dis 2006; 36: 53-58.
3. Taddei TH, Kacena KA, Yang M, et al. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol 2009; 84: 208-214.
4. Rosenbloom BE, Weinreb NJ, Zimran A, et al. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 2005; 105: 4569-4572.
5. Benjamin D, Joshua H, Djaldetti M, et al. Nonsecretory IgD-kappa multiple myeloma in a patient with Gaucher's disease. Scand J Haematol 1979; 22: 179-184.
6. Fox H, McCarthy P, Andre-Schwartz J, et al. Gaucher's disease and chronic lymphocytic leukemia. Possible pathogenetic link between Gaucher's disease and B-cell proliferations? Cancer 1984; 54: 312-314.
7. Garfinkel D, Sidi Y, Ben Bassat M, et al. Coexistence of Gaucher's disease and multiple myeloma. Arch Intern Med 1982; 142: 2229-2230.
8. Harder H, Eucker J, Zang C, et al. Coincidence of Gaucher's disease due to a 1226G/1448C mutation and of an immunoglobulin G lambda multiple myeloma with Bence-Jones proteinuria. Ann Hematol 2000; 79: 640-643.
9. Weinreb NJ, Lee RE. Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher disease who were never treated with enzyme replacement therapy. Crit Rev Oncog 2013; 18: 177-195.
10. Allen MJ, Myer BJ, Khokher AM, et al. Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. QJM 1997; 90: 19-25.
11. de Fost M, Out TA, de Wilde FA, et al. Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann Hematol 2008; 87: 439-449.
12. Arends M, van Dussen L, Biegstraaten M, et al. Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature. Br J Haematol 2013; 161: 832-842.
13. Cox TM. Gaucher disease: understanding themolecular pathogenesis of sphingolipidoses. J Inherit Metab Dis 2001; 24: 106-121.
14. Boot RG, Verhoek M, de Fost M, et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 2004; 103: 33-39.
15. Moran MT, Schofield JP, Hayman AR, et al. Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood 2000; 96: 1969-1978.
16. Boven LA, van Meurs M, Boot RG, et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 2004; 122: 359-369.
17. Barak V, Acker M, Nisman B, et al. Cytokines in Gaucher's disease. Eur Cytokine Netw 1999; 10: 205-210.
18. Lichtenstein M, Zimran A, Horowitz M. Cytokine mRNA in Gaucher disease. Blood Cells Mol Dis 1997; 23: 395-401.
19. Dekker N, van Dussen L, Hollak CE, et al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood 2011; 118: 118-127.
20. Lahiri S, Futerman AH. The metabolism and function of sphingolipids and glycosphingolipids. Cell Mol Life Sci 2007; 64: 2270-2284.
21. Radin NS. Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj J 1996; 13: 153-157.
22. Pavlova EV, Wang SZ, Archer J, et al. B cell lymphoma and myeloma in murine Gaucher's disease. J Pathol 2013; 231: 88-97.
23. Radin NS, Arora RC, Ullman MD, et al. A possible therapeutic approach to Krabbe's globoid leukodystrophy and the status of cerebroside synthesis in the disorder. Res Commun Chem Pathol Pharmacol 1972; 3: 637-644.
24. Vunnam RR, Radin NS. Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain. Chem Phys Lipids 1980; 26: 265-278
25. Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher's disease with N -butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000; 355: 1481-1485.
26. Elstein D, Hollak C, Aerts JM, et al. Sustained therapeutic effects of oral miglustat (Zavesca, N -butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 2004; 27: 757-766.
27. Cox TM, Aerts JM, Andria G, et al. The role of the iminosugar N -butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. Advisory Council to the European Working Group on Gaucher Disease. J Inherit Metab Dis 2003; 26: 513-526.
28. Cox TM, Amato D, Hollak CEM, et al. Miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease. Orphanet J Rare Dis 2012; 7: 102.
29. Lee L, Abe A, Shayman JA. Improved inhibitors of glucosylceramide synthase. J Biol Chem 1999; 274: 14662-14669.
30. Shayman JA. Eliglustat tartrate: glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease. Drugs Future 2010; 35: 613-620.
31. McEachern KA, Fung J, Komarnitsky S, et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab 2007; 91: 259-267.
32. Marshall J, McEachern KA, Chuang WL, et al. Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy. J Inherit Metab Dis 2010; 33: 281-289.
33. Peterschmitt MJ, Burke A, Blankstein L, et al. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers. J Clin Pharmacol 2011; 51: 695-705.
34. Lukina E, Watman N, Arreguin EA, et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood 2010; 116: 4095-4098.
35. Lukina E, Watman N, Arreguin EA, et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Erratum. Blood 2011; 117: 5551.
36. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nature Rev Mol Cell Biol 2008; 9: 139-150.
37. Abe A, Radin NS, Shayman JA, et al. Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. J Lipid Res 1995; 36: 611-621.
38. Chatterjee S, Alsaeedi N, Hou J, et al. Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model. PLoS One 2013; 8: e63726.
39. Manning LS, Radin NS. Effects of the glucolipid synthase inhibitor P4 on functional and phenotypic parameters of murine myeloma cells. Br J Cancer 1999; 81: 952-958.
40. Natoli TA, Smith LA, Rogers KA, et al. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nature Med 2010; 16: 788-792.
41. Enquist IB, Nilsson E, Ooka A, et al. Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci U S A 2006; 103: 13819-13824.
42. Elmore SA. Enhanced histopathology of the spleen. Toxicol Pathol 2006; 34: 648-655.
43. Svennerholm L, Vanier MT, Mansson JE. Krabbe disease: a galactosylsphingosine (psychosine) lipidosis. J Lipid Res 1980; 21: 53-64.
44. Yamaguchi Y, Sasagasako N, Goto I, et al. The synthetic pathway for glucosylsphingosine in cultured fibroblasts. J Biochem 1994; 116: 704-710.
45. Kanazawa T, Nakamura S, Momoi M, et al. Inhibition of cytokinesis by a lipid metabolite, psychosine. J Cell Biol 2000; 149: 943-950.
46. Im DS, Heise CE, Nguyen T, et al. Identification of a molecular target of psychosine and its role in globoid cell formation. J Cell Biol 2001; 153: 429-434.
47. Belleri M, Ronca R, Coltrini D, et al. Inhibition of angiogenesis by β-galactosylceramidase deficiency in globoid cell leukodystrophy. Brain 2013; 136: 2859-2875.
48. Presta M., Belleri M., Cox TM, et al. The role of the endothelium in globoid-cell leukodystrophy: unexpected revelations. Future Neurol 2014, 9: 127-130.
49. Mizukami H, Mi Y, Wada R, et al. Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. J Clin Invest 2002; 109: 1215-1221.
50. Liu J, Halene S, Yang M, et al. Gaucher disease gene GBA functions in immune regulation. Proc Natl Acad Sci U S A 2012; 109: 10018-10023.
51. Mistry PK, Liu J, Yang M, et al. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci U S A 2010; 107: 19473-19478.
52. Cox TM. Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases. Curr Opin Investig Drugs 2010; 11: 1169-1181.
53. Platt FM, Reinkensmeier G, Dwek RA, et al. Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N -butyldeoxynojirimycin. J Biol Chem 1997; 272: 19365-19372.
54. Inokuchi J, Mason I, Radin NS. Antitumor activity via inhibition of glycosphingolipid biosynthesis. Cancer Lett 1987; 38: 23-30.
55. Radin NS, Inokuchi J. Glucosphingolipids as sites of action in the chemotherapy of cancer. Biochem Pharmacol 1988; 37: 2879-2886.
56. Radin NS, Shayman JA, Inokuchi J. Metabolic effects of inhibiting glucosylceramide synthesis with PDMP and other substances. Adv Lipid Res 1993; 26: 183-213.
57. Radin NS. Killing tumours by ceramide-induced apoptosis: a critique of available drugs. Biochem J 2003; 371: 243-256.
58. Brady RO. Enzyme replacement for lysosomal diseases. Annu Rev Med 2006; 57: 283-296.
59. Deegan PB, Cox TM. Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des Dev Ther 2012; 6: 81-106.
60. Weinreb NJ, Goldblatt J, Villalobos J, et al. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis 2013; 36: 543-553. Erratum in J Inherit Metab Dis 2014; 37: 147.